Physiologically Based Pharmacokinetic (PBPK) Modeling of Rifampicin and Its Application for Drug-Drug Interaction with Midazolam in Adults​

Authors: Avvari S, Szeto KX, Lukacova V, Bolger MB, Fraczkiewicz G, Chapi R, Vora TB
Conference: AAPS
Keywords: AAPS 2022, drug-drug interactions (DDIs), midazolam, PBPK modeling, Rifampicin
Software: GastroPlus®
Division: PBPK

Purpose​

Rifampicin (RIF) is an essential part of tuberculosis therapy and the pharmacokinetics (PK) of RIF has been of interest due to its non-linear and auto-induction behavior.  RIF acts as a perpetrator, causing clinically relevant drug-drug interactions (DDIs) via induction and inhibition of multiple metabolic enzymes and transporters. 

By Suvarchala Avvari, Ke Szeto, Viera Lukacova, Michael B. Bolger, ​Grace Fraczkiewicz, Revathi Chapa, Tarang Vora

Presented at American Association of Pharmaceutical Scientists (AAPS) Pharm Sci 360 Boston, Massachusetts October 16-19, 2022​